318 CHAPTER 4.1 Table SI1.2. Continued START criteria (n=31) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) E 1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 14 28.6% 1 0% 5 40.0% 4 50.0% 4 0% C 6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron deficiency and severe renal failure have been excluded. 9 11.1% 1 100% 7 0% 0 N/A 1 0% B 2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of predicted value and repeated exacerbations requiring treatment with oral corticosteroids. 8 25.0% 0 N/A 7 14.3% 0 N/A 1 100% C 3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for mildmoderate Alzheimer’s dementia or Lewy Body dementia (rivastigmine). 8 12.5% 0 N/A 4 0% 1 100% 3 0% D 1. Proton Pump Inhibitor with severe gastrooesophageal reflux disease or peptic stricture requiring dilatation. 8 37.5% 1 100% 5 20.0% 1 100% 1 0% C 1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant disability. 3 0% 0 N/A 2 0% 1 0% 0 N/A
RkJQdWJsaXNoZXIy MTk4NDMw